(Q34663603)

3 August 2017

title

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study (English)

1 reference

3 August 2017

Ian W Flinn

1

0 references

author name string

Richard van der Jagt

2

1 reference

3 August 2017

Brad S Kahl

3

1 reference

3 August 2017

Peter Wood

4

1 reference

3 August 2017

Tim E Hawkins

5

1 reference

3 August 2017

David Macdonald

6

1 reference

3 August 2017

Mark Hertzberg

7

1 reference

3 August 2017

Yiu-Lam Kwan

8

1 reference

3 August 2017

David Simpson

9

1 reference

3 August 2017

Michael Craig

10

1 reference

3 August 2017

Kathryn Kolibaba

11

1 reference

3 August 2017

Samar Issa

12

1 reference

3 August 2017

Regina Clementi

13

1 reference

3 August 2017

Doreen M Hallman

14

1 reference

3 August 2017

Mihaela Munteanu

15

1 reference

3 August 2017

Ling Chen

16

1 reference

3 August 2017

John M Burke

17

1 reference

3 August 2017

language of work or name

English

0 references

publication date

3 March 2014

1 reference

3 August 2017

1 reference

3 August 2017

volume

123

1 reference

3 August 2017

issue

19

1 reference

3 August 2017

page(s)

2944-2952

1 reference

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Follicular lymphoma in the United States: first report of the national LymphoCare study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Revised response criteria for malignant lymphoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260975

Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24591201

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24591201

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Selection of first-line therapy for advanced follicular lymphoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24591201

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2013-11-531327

1 reference

3 August 2017

1 reference

3 August 2017

1 reference